Elite Pharmaceuticals (OTCMKTS:ELTP) Shares Pass Below 200-Day Moving Average - Time to Sell?

Key Points

• Shares fell below the 200‑day moving average: ELTP traded under its 200‑day MA of $0.49, hitting a low of $0.3753 and last trading at $0.3875 on a volume of 220,515 shares.
• Underlying fundamentals appear strong: the company has a $417.39M market cap, P/E of 12.92, quarterly EPS of $0.01 on $31.59M revenue, a net margin of 30.98% and ROE of 47.93%, with high liquidity (current ratio 7.34, quick ratio 5.44) and very low leverage (debt/equity 0.05).

Shares of Elite Pharmaceuticals Inc. (OTCMKTS:ELTP - Get Free Report) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.49 and traded as low as $0.3753. Elite Pharmaceuticals shares last traded at $0.3875, with a volume of 220,515 shares traded.

Elite Pharmaceuticals Stock Up 2.0%

The company has a market cap of $417.39 million, a P/E ratio of 12.92 and a beta of 0.46. The stock's 50-day moving average price is $0.39 and its 200-day moving average price is $0.49. The company has a current ratio of 7.34, a quick ratio of 5.44 and a debt-to-equity ratio of 0.05.

Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) last released its quarterly earnings data on Tuesday, February 17th. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $31.59 million for the quarter. Elite Pharmaceuticals had a net margin of 30.98% and a return on equity of 47.93%.

About Elite Pharmaceuticals

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.